Is Now the Time to Go All-In On Novavax Stock?
On June 14, Novavax (NASDAQ: NVAX) announced that its recombinant nanoparticle coronavirus vaccine, NVX-CoV2373, had demonstrated 93% overall efficacy against coronavirus variants in phase 3 trials -- and that number shot up to 100% for severe or critical COVID-19. The vaccine candidate was also well-tolerated, with serious adverse events spread out equally between placebo and treatment groups. Shares fell about 10% after Novavax published the results.